Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 EUR | -1.37% | +1.41% | +5.11% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 244.6 | 184.3 | 186.2 | 171 | 130.2 | 136.8 | - | - |
Enterprise Value (EV) 1 | 244.6 | 184.3 | 186.2 | 171 | 130.2 | 136.8 | 136.8 | 136.8 |
P/E ratio | - | - | - | - | - | - | - | - |
Yield | 0.97% | - | - | - | - | 1.39% | 1.39% | 8.33% |
Capitalization / Revenue | 0.36 x | 0.28 x | 0.28 x | 0.24 x | 0.18 x | 0.19 x | 0.18 x | 0.18 x |
EV / Revenue | 0.36 x | 0.28 x | 0.28 x | 0.24 x | 0.18 x | 0.19 x | 0.18 x | 0.18 x |
EV / EBITDA | 2.61 x | 2.38 x | 2.18 x | 1.88 x | 1.32 x | 1.46 x | 1.41 x | 1.35 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | 1.28 x | 1.04 x | 1.02 x | 0.82 x | 0.66 x | 0.64 x | 0.59 x | 0.54 x |
Nbr of stocks (in thousands) | 47,500 | 47,500 | 47,500 | 47,500 | 47,500 | 47,500 | - | - |
Reference price 2 | 5.150 | 3.880 | 3.920 | 3.600 | 2.740 | 2.880 | 2.880 | 2.880 |
Announcement Date | 3/26/20 | 3/8/21 | 3/30/22 | 3/31/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 673.1 | 659.9 | 673.1 | 704.7 | 730.1 | 730 | 751.9 | 763.2 |
EBITDA 1 | 93.58 | 77.5 | 85.22 | 90.92 | 98.73 | 93.77 | 97.29 | 101 |
EBIT 1 | 22.41 | 0.1507 | 11.56 | 19.52 | 12.72 | 39.78 | 43.23 | 45.79 |
Operating Margin | 3.33% | 0.02% | 1.72% | 2.77% | 1.74% | 5.45% | 5.75% | 6% |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
Net income 1 | 9.662 | -8.997 | 1.461 | 9.441 | -10.78 | 16.56 | 20.31 | 23.25 |
Net margin | 1.44% | -1.36% | 0.22% | 1.34% | -1.48% | 2.27% | 2.7% | 3.05% |
EPS | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | 0.0500 | - | - | - | - | 0.0400 | 0.0400 | 0.2400 |
Announcement Date | 3/26/20 | 3/8/21 | 3/30/22 | 3/31/23 | 3/27/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 4.020 | 3.730 | 3.860 | 4.400 | 4.130 | 4.480 | 4.860 | 5.310 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/26/20 | 3/8/21 | 3/30/22 | 3/31/23 | 3/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.11% | 147M | |
-15.68% | 17.21B | |
+4.50% | 12.54B | |
+4.48% | 11.71B | |
+3.44% | 10.43B | |
+26.66% | 8.51B | |
-1.92% | 7.74B | |
+20.39% | 7.18B | |
+3.42% | 6.55B | |
+46.01% | 4.5B |
- Stock Market
- Equities
- MED Stock
- Financials MEDICLIN AG